USPTO Grants Notice Of Allowance For Additional Patent On IceCure's Novel 'Cryogenic Pump' Technology, Reinforcing Co's Global IP Leadership in Cryoablation Technologies
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical Ltd. (NASDAQ:ICCM) has received a Notice of Allowance from the USPTO for a continuation patent on its 'Cryogenic Pump' technology, enhancing its global IP leadership in cryoablation technologies. This patent broadens the applications of IceCure's platform, with over 50 patents issued worldwide.
August 28, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical has been granted a Notice of Allowance for a continuation patent by the USPTO for its 'Cryogenic Pump' technology. This strengthens its intellectual property portfolio and broadens the applications of its cryoablation platform.
The granting of a new patent by the USPTO is a positive development for IceCure Medical, as it reinforces the company's intellectual property position and expands the potential applications of its technology. This could lead to increased investor confidence and potential market opportunities, likely having a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100